Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Active ANCA-associated Vasculitis
NCT06388941Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of Iptacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by Novartis. Started Aug 2024; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT06388941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388941.